Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation.
Aging is strictly associated with an increased incidence of cardiovascular events (CVEs) in the general population. Mechanisms underlying the risk of CVEs are still unclear. Platelet activation contributes to the onset of cardiovascular complications. The incidence of atrial fibrillation (AF) increases with age, and the natural history of AF is often complicated by CVEs. We prospectively investigated the relationship between age, urinary thromboxane (Tx) B2, which reflects platelet activation, and CVEs in 833 AF patients. Median TxB2 level was 120 [66-200] ng/mg of urinary creatinine. At multivariable linear regression analysis, age (B: 0.097, p=0.005) and previous MI/CHD (B: 0.069, p=0.047) were associated with log-TxB2 levels. When we divided our population into age classes (i.e. < 60, 60-69, 70-79, ≥ 80 years), we found a significant difference in TxB2 levels across classes (p=0.005), with a significant elevation at 74.6 years. During a mean follow-up of 40.9 months, 128 CVEs occurred; the rate of CVEs significantly increased with age classes (Log-rank test, p < 0.001). TxB2 levels were higher in patients with, compared to those without, CVEs in patients aged 70-79 (p < 0.001) and ≥ 80 (p = 0.020) years. In conclusion, TxB2 levels enhance by increasing age, suggesting that platelet activation contributes to CVEs in elderly patients with AF.
I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Daniele
D
Pastori
I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Pasquale
P
Pignatelli
Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy.
Alessio
A
Farcomeni
I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Cristina
C
Nocella
I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Simona
S
Bartimoccia
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Roberto
R
Carnevale
I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Francesco
F
Violi
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000886:Anthropometry; D001281:Atrial Fibrillation / Q000150:complications / Q000652:urine*; D002318:Cardiovascular Diseases / Q000150:complications / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015539:Platelet Activation; D011446:Prospective Studies; D012044:Regression Analysis; D012306:Risk; D013929:Thromboxane B2 / Q000235:genetics / Q000652:urine*
D013929:Thromboxane B2
Gerotarget; aging; atrial fibrillation; cardiovascular disease; platelet; thromboxane